The company sources critical raw materials and active pharmaceutical ingredients (APIs) primarily from 39 suppliers in Europe and China. It also obtains specialized laboratory equipment, supplies, materials, and precursor compounds from multiple countries outside the United States. Contract manufacturing organizations in its supply chain may be subject to U.S. legislation, trade restrictions, sanctions, tariffs, and other regulatory requirements, which could disrupt supply or increase manufacturing costs. The BIOSECURE Act, part of the National Defense Authorization Act for fiscal year 2026, restricts U.S. government procurement and contracts involving biotechnology equipment or services from designated "biotechnology companies of concern" (BCC), including those listed on the U.S. Department of Defense’s List of Chinese Military Companies (1260H List). These restrictions may limit the company's ability to collaborate with certain Chinese biotechnology companies if it receives U.S. government funding. Tariffs and trade restrictions could increase costs, complicate the supply chain, delay clinical trials, and adversely affect development timelines and financing.
Equillium Inc's Comment on Supply Chain
The company sources critical raw materials and active pharmaceutical ingredients (APIs) primarily from 39 suppliers in Europe and China. It also obtains specialized laboratory equipment, supplies, materials, and precursor compounds from multiple countries outside the United States. Contract manufacturing organizations in its supply chain may be subject to U.S. legislation, trade restrictions, sanctions, tariffs, and other regulatory requirements, which could disrupt supply or increase manufacturing costs. The BIOSECURE Act, part of the National Defense Authorization Act for fiscal year 2026, restricts U.S. government procurement and contracts involving biotechnology equipment or services from designated "biotechnology companies of concern" (BCC), including those listed on the U.S. Department of Defense’s List of Chinese Military Companies (1260H List). These restrictions may limit the company's ability to collaborate with certain Chinese biotechnology companies if it receives U.S. government funding. Tariffs and trade restrictions could increase costs, complicate the supply chain, delay clinical trials, and adversely affect development timelines and financing.
Sources:
Equillium Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Equillium Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
